Preliminary results from TRITON2 demonstrate efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in ~50% of patients with metastatic castration-resistant prostate cancer and inactivation of BRCA1/BRCA2. However, those with ATM and CDK12 mutations do not seem to benefit. An improved homologous recombination deficiency test must be developed and alternative treatments defined for these subsets of patients.
|Original language||English (US)|
|Number of pages||3|
|Journal||Nature Reviews Urology|
|State||Published - Jan 1 2019|
Bibliographical noteFunding Information:
This work was partially supported by NIH Cancer Center Support Grant P30 CA006973, the Department of Defense (DOD) grant W81XWH-16-PCRP-CCRSA, NIH grant R01 CA185297, and US Department of Defense Prostate Cancer Research Program grant W81XWH-15-2-0050, and the Patrick C. Walsh Research Fund.
© 2018, Springer Nature Limited.